#76 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Suzetrigine’s demonstrated ability to reduce postoperative opioid requirements offers clinicians a non-opioid alternative for acute pain management, potentially decreasing opioid-related adverse effects and addiction risk in surgical patients. This finding is particularly relevant given the ongoing opioid crisis, as adopting such adjunctive analgesics could lower overall opioid exposure while maintaining adequate pain control. Patients may benefit from safer postoperative pain management protocols that minimize dependence risk without compromising analgesia.
Suzetrigine, a selective sodium channel blocker in clinical development, demonstrated safety and tolerability in postoperative pain management with no serious adverse drug-related events reported. The available evidence suggests potential for reducing postoperative opioid requirements when used as part of a multimodal pain management approach, which has implications for decreasing opioid exposure and related harms in the acute surgical setting. While the article title references a cannabis-opioid combination, the clinical data presented focus on suzetrigine’s role in opioid-sparing analgesia, highlighting an emerging pharmacologic alternative for acute pain control. For clinicians managing postoperative pain, these findings underscore the value of exploring non-opioid and opioid-reducing strategies to minimize opioid dependence risk while maintaining adequate analgesia. Clinicians should consider suzetrigine and similar analgesic alternatives as part of enhanced recovery after surgery protocols, particularly for patients at high risk of opioid-related complications.
“What we’re seeing with suzetrigine and other non-opioid analgesics is validation of what cannabis medicine practitioners have long observed: patients genuinely prefer and respond better to multimodal pain management that doesn’t rely on opioids, and when we offer them that choice, they use fewer opioids overall. This changes how I think about acute postoperative pain now.”
🩺 As evidence accumulates for non-opioid analgesics like suzetrigine in postoperative pain management, clinicians should recognize that cannabis adjunctive therapy remains an understudied and legally variable option that may appeal to patients seeking to reduce opioid exposure. While suzetrigine’s safety profile in early trials is encouraging, the heterogeneity of cannabis products, limited high-quality evidence on postoperative efficacy, and variability in state-level legal status create significant barriers to standardized clinical recommendations. The combination of novel synthetic analgesics with cannabis-based approaches requires substantially more rigorous clinical trials to establish optimal dosing, drug interactions, and patient selection criteria before widespread adoption can be justified. Given these evidence gaps, clinicians should remain cautious about recommending cannabis for perioperative pain while continuing to implement established multimodal analgesia strategies and considering emerging non-opioid pharmaceuticals with clearer
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
